Cellular entry of human papillomavirus type 16 involves activation of the phosphatidylinositol 3-kinase/Akt/mTOR pathway and inhibition of autophagy

Journal of Virology

Volumn 87, Issue 5, 2013, Pages 2508-2517

  Surviladze, Zurab ^a   Sterk, Rosa T ^a   DeHaro, Sergio A ^a   Ozbun, Michelle A ^a  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BP1; PROTEIN KINASE B; PROTEIN S6K; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR;

ARTICLE; AUTOPHAGY; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; KERATINOCYTE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; SIGNAL TRANSDUCTION; VIRION; VIRUS CELL INTERACTION; VIRUS ENTRY;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; AUTOPHAGY; CELL CYCLE; CELL LINE; EUKARYOTIC INITIATION FACTOR-4G; HEK293 CELLS; HUMAN PAPILLOMAVIRUS 16; HUMANS; KERATINOCYTES; PAPILLOMAVIRUS INFECTIONS; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOPROTEINS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; VIRUS INTERNALIZATION;

EID: 84874716169     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02319-12     Document Type: Article

References (81)

1. Surviladze Z, Dziduszko A, Ozbun MA. 2012. Essential roles for soluble virion-associated heparan sulfonated proteoglycans and growth factors in human papillomavirus infections. PLoS Pathog. 8:e1002519. doi:10.1371 /journal.ppat.1002519.
2. Marsh M, Helenius A. 2006. Virus entry: open Sesame. Cell 124:729-740.
3. Andjelkovic M, Alessi DR, Meier R, Fernandez A, Lamb NJ, Frech M, Cron P, Cohen P, Lucocq JM, Hemmings BA. 1997. Role of translocation in the activation and function of protein kinase B. J. Biol. Chem. 272:31515-31524.
4. Buchkovich NJ, Yu Y, Zampieri CA, Alwine JC. 2008. The TORrid affairs of viruses: effects of mammalian DNA viruses on the PI3K-AktmTOR signalling pathway. Nat. Rev. Microbiol. 6:266-275.
5. Cooray S. 2004. The pivotal role of phosphatidylinositol 3-kinase-Akt signal transduction in virus survival. J. Gen. Virol. 85:1065-1076.
6. Pópulo H, Lopes JM, Soares P. 2012. The mTOR signalling pathway in human cancer. Int. J. Mol. Sci. 13:1886-1918.
7. Porstmann T, Santos CR, Griffiths B, Cully M, Wu M, Leevers S, Griffiths JR, Chung YL, Schulze A. 2008. SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth. Cell Metab. 8:224-236.
8. Schieke SM, Phillips D, McCoy JP, Jr, Aponte AM, Shen RF, Balaban RS, Finkel T. 2006. The mammalian target of rapamycin (mTOR) pathway regulates mitochondrial oxygen consumption and oxidative capacity. J. Biol. Chem. 281:27643-27652.
9. Hay N, Sonenberg N. 2004. Upstream and downstream of mTOR. Genes Dev. 18:1926-1945.
10. Petroulakis E, Mamane Y, Le Bacquer O, Shahbazian D, Sonenberg N. 2006.mTORsignaling: implications for cancer and anticancer therapy. Br. J. Cancer 94:195-199.
11. Crusius K, Auvinen E, Steuer B, Gaissert H, Alonso A. 1998. The human papillomavirus type 16 E5-protein modulates ligand-dependent activation of the EGF receptor family in the human epithelial cell line HaCaT. Exp. Cell Res. 241:76-83.
12. Jacinto E, Loewith R, Schmidt A, Lin S, Ruegg MA, Hall A, Hall MN. 2004. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat. Cell Biol. 6:1122-1128.
13. Alessi DR, Pearce LR, Garcia-Martinez JM. 2009. New insights into mTOR signaling: mTORC2 and beyond. Sci. Signal. 2:pe27. doi:10.1126 /scisignal.267pe27.
14. Jacinto E, Facchinetti V, Liu D, Soto N, Wei S, Jung SY, Huang Q, Qin J, Su B. 2006. SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 127:125-137.
15. Ma XM, Blenis J. 2009. Molecular mechanisms of mTOR-mediated translational control. Nat. Rev. Mol. Cell Biol. 10:307-318.
16. Fan QW, Weiss WA. 2011. Autophagy and Akt promote survival in glioma. Autophagy 7:536-538.
17. Mammucari C, Milan G, Romanello V, Masiero E, Rudolf R, Del Piccolo P, Burden SJ, Di Lisi R, Sandri C, Zhao J, Goldberg AL, Schiaffino S, Sandri M. 2007. FoxO3 controls autophagy in skeletal muscle in vivo. Cell Metab. 6:458-471.
18. Deretic V, Levine B. 2009. Autophagy, immunity, and microbial adaptations. Cell Host Microbe 5:527-549.
19. Jordan TX, Randall G. 2012. Manipulation or capitulation: virus interactions with autophagy. Microbes Infect. 14:126-139.
20. Menges CW, Baglia LA, Lapoint R, McCance DJ. 2006. Human papillomavirus type 16 E7 up-regulates AKT activity through the retinoblastoma protein. Cancer Res. 66:5555-5559.
21. Pim D, Massimi P, Dilworth SM, Banks L. 2005. Activation of the protein kinase B pathway by the HPV-16 E7 oncoprotein occurs through a mechanism involving interaction with PP2A. Oncogene 24:7830-7838.
22. Spangle JM, Munger K. 2010. The human papillomavirus type 16 E6 oncoprotein activates mTORC1 signaling and increases protein synthesis. J. Virol. 84:9398-9407.
23. Abban CY, Meneses PI. 2010. Usage of heparan sulfate, integrins, and FAK in HPV16 infection. Virology 403:1-16.
24. Payne E, Bowles MR, Don A, Hancock JF, McMillan NAJ. 2001. Human papillomavirus type 6b virus-like particles are able to activate the Ras-MAP kinase pathway and induce cell proliferation. J. Virol. 75:4150-4157.
25. Schelhaas M, Shah B, Holzer M, Blattmann P, Kühling L, Day PM, Schiller JT, Helenius A. 2012. Entry of human papillomavirus type 16 by actin-dependent, clathrin-and lipid raft-independent endocytosis. PLoS Pathog. 8:e1002657. doi:10.1371/journal.ppat.1002657.
26. Fothergill T, McMillan NAJ. 2006. Papillomavirus virus-like particles activate the PI3-kinase pathway via alpha-6 beta-4 integrin upon binding. Virology 352:319-328.
27. Campos SK, Ozbun MA. 2009. Two highly conserved cysteine residues in HPV16 L2 form an intramolecular disulfide bond and are critical for infectivity in human keratinocytes. PLoS One 4:e4463. doi:10.1371/journal .pone.0004463.
28. Ozbun MA, Kivitz MP. 2011. The art and science of obtaining virion stocks for experimental human papillomavirus infections, p 19-35. In Gaston K (ed), Small DNA tumor viruses. Horizon Scientific and Caister Academic Press, Norfolk, United Kingdom.
29. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. 2005. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307:1098-1101.
30. Culp TD, Budgeon LR, Christensen ND. 2006. Human papillomaviruses bind a basal extracellular matrix component secreted by keratinocytes which is distinct from a membrane-associated receptor. Virology 347: 147-159.
31. Joyce JG, Tung J-S, Przysiecki CT, Cook JC, Lehman ED, Sands JA, Jansen KU, Keller PM. 1999. The L1 major capsid protein of human papillomavirus type 11 recombinant virus-like particles interacts with heparin and cell-surface glycosaminoglycans on human keratinocytes. J. Biol. Chem. 274:5810-5822.
32. Shafti-Keramat S, Handisurya A, Kriehuber E, Meneguzzi G, Slupetzky K, Kirnbauer R. 2003. Different heparan sulfate proteoglycans serve as cellular receptors for human papillomaviruses. J. Virol. 77:13125-13135.
33. Day PM, Gambhira R, Roden R, Lowy DR, Schiller JT. 2008. Mechanisms of human papillomavirus type 16 neutralization by L2 crossneutralizing and L1 type-specific antibodies. J. Virol. 82:4638-4646.
34. Vazquez F, Ramaswamy S, Nakamura N, Sellers WR. 2000. Phosphorylation of the PTEN tail regulates protein stability and function. Mol. Cell. Biol. 20:5010-5018.
35. Ono M, Kuwano M. 2006. Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs. Clin. Cancer Res. 12:7242-7251.
36. Guertin DA, Sabatini DM. 2007. Defining the role of mTOR in cancer. Cancer Cell 12:9-22.
37. Manning BD, Cantley LC. 2007. AKT/PKB signaling: navigating downstream. Cell 129:1261-1274.
38. Nave BT, Ouwens M, Withers DJ, Alessi DR, Shepherd PR. 1999. Mammalian target of rapamycin is a direct target for protein kinase B: identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation. Biochem. J. 344(Part 2): 427-431.
39. Peterson RT, Beal PA, Comb MJ, Schreiber SL. 2000. FKBP12-rapamycin-associated protein (FRAP) autophosphorylates at serine 2481 under translationally repressive conditions. J. Biol. Chem. 275:7416-7423.
40. Holz MK, Ballif BA, Gygi SP, Blenis J. 2005. mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events. Cell 123:569-580.
41. Burnett PE, Barrow RK, Cohen NA, Snyder SH, Sabatini DM. 1998. RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1. Proc. Natl. Acad. Sci. U. S. A. 95:1432-1437.
42. Gingras AC, Gygi SP, Raught B, Polakiewicz RD, Abraham RT, Hoekstra MF, Aebersold R, Sonenberg N. 1999. Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism. Genes Dev. 13:1422-1437.
43. Donepudi M, Resh MD. 2008. c-Src trafficking and co-localization with the EGF receptor promotes EGF ligand-independent EGF receptor activation and signaling. Cell. Signal. 20:1359-1367.
44. Sandilands E, Akbarzadeh S, Vecchione A, McEwan DG, Frame MC, Heath JK. 2007. Src kinase modulates the activation, transport and signalling dynamics of fibroblast growth factor receptors. EMBO Rep. 8:1162-1169.
45. Nijhuis E, Lammers JW, Koenderman L, Coffer PJ. 2002. Src kinases regulate PKB activation and modulate cytokine and chemoattractantcontrolled neutrophil functioning. J. Leukoc. Biol. 71:115-124.
46. Choo AY, Blenis J. 2009. Not all substrates are treated equally: implications for mTOR, rapamycin-resistance and cancer therapy. Cell Cycle 8:567-572.
47. Vu C, Fruman DA. 2010. Target of rapamycin signaling in leukemia and lymphoma. Clin. Cancer Res. 16:5374-5380.
48. Gingras AC, Raught B, Gygi SP, Niedzwiecka A, Miron M, Burley SK, Polakiewicz RD, Wyslouch-Cieszynska A, Aebersold R, Sonenberg N. 2001. Hierarchical phosphorylation of the translation inhibitor 4E-BP1. Genes Dev. 15:2852-2864.
49. Jung CH, Ro SH, Cao J, Otto NM, Kim DH. 2010. mTOR regulation of autophagy. FEBS Lett. 584:1287-1295.
50. Wang X, Proud CG. 2011. mTORC1 signaling: what we still don't know. J. Mol. Cell. Biol. 3:206-220.
51. Kabeya Y, Mizushima N, Ueno T, Yamamoto A, Kirisako T, Noda T, Kominami E, Ohsumi Y, Yoshimori T. 2000. LC3, a mammalian homo-logue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J. 19:5720-5728.
52. Scarlatti F, Bauvy C, Ventruti A, Sala G, Cluzeaud F, Vandewalle A, Ghidoni R, Codogno P. 2004. Ceramide-mediated macroautophagy involves inhibition of protein kinase B and up-regulation of beclin 1. J. Biol. Chem. 279:18384-18391.
53. Smith JL, Lidke DS, Ozbun MA. 2008. Virus activated filopodia promote human papillomavirus type 31 uptake from the extracellular matrix. Virology 381:16-21.
54. Vanhaesebroeck B, Leevers SJ, Ahmadi K, Timms J, Katso R, Driscoll PC, Woscholski R, Parker PJ, Waterfield MD. 2001. Synthesis and function of 3-phosphorylated inositol lipids. Annu. Rev. Biochem. 70: 535-602.
55. Raught B, Gingras AC, Sonenberg N. 2001. The target of rapamycin (TOR) proteins. Proc. Natl. Acad. Sci. U. S. A. 98:7037-7044.
56. Altan N, Chen Y, Schindler M, Simon SM. 1999. Tamoxifen inhibits acidification in cells independent of the estrogen receptor. Proc. Natl. Acad. Sci. U. S. A. 96:4432-4437.
57. Caro LH, Plomp PJ, Wolvetang EJ, Kerkhof C, Meijer AJ. 1988. 3-Methyladenine, an inhibitor of autophagy, has multiple effects on metabolism. Eur. J. Biochem. 175:325-329.
58. Lopes MC, Vale MG, Carvalho AP. 1990. Ca2(+)-dependent binding of tamoxifen to calmodulin isolated from bovine brain. Cancer Res. 50: 2753-2758.
59. O'Brian CA, Housey GM, Weinstein IB. 1988. Specific and direct binding of protein kinase C to an immobilized tamoxifen analogue. Cancer Res. 48:3626-3629.
60. Wiseman H, Cannon M, Arnstein HR, Halliwell B. 1990. Mechanism of inhibition of lipid peroxidation by tamoxifen and 4-hydroxytamoxifen introduced into liposomes. Similarity to cholesterol and ergosterol. FEBS Lett. 274:107-110.
61. Wu Y-T, Tan H-L, Shui G, Bauvy C, Huang Q, Wenk MR, Ong C-N, Codogno P, Shen H-M. 2010. Dual role of 3-methyladenine in modulation of autophagy via different temporal patterns of inhibition on class I and III phosphoinositide 3-kinase. J. Biol. Chem. 285:10850-10861.
62. Pyeon D, Pearce SM, Lank SM, Ahlquist P, Lambert PF. 2009. Establishment of human papillomavirus infection requires cell cycle progression. PLoS Pathog. 5:e1000318. doi:10.1371/journal.ppat.1000318.
63. Ji WT, Liu HJ. 2008. PI3K-Akt signaling and viral infection. Recent Pat. Biotechnol. 2:218-226.
64. Zyzak LL, MacDonald LM, Batova A, Forand R, Creek KE, Pirisi L. 1994. Increased levels and constitutive tyrosine phosphorylation of the epidermal growth factor receptor contribute to autonomous growth of human papillomavirus type 16 immortalized human keratinocytes. Cell Growth Differ. 5:537-547.
65. Mariotti A, Kedeshian PA, Dans M, Curatola AM, Gagnoux-Palacios L, Giancotti FG. 2001. EGF-R signaling through Fyn kinase disrupts the function of integrin alpha6beta4 at hemidesmosomes: role in epithelial cell migration and carcinoma invasion. J. Cell Biol. 155:447-458.
66. Sterk LM, Geuijen CA, Oomen LC, Calafat J, Janssen H, Sonnenberg A. 2000. The tetraspan molecule CD151, a novel constituent of hemidesmosomes, associates with the integrin alpha6beta4 and may regulate the spatial organization of hemidesmosomes. J. Cell Biol. 149:969-982.
67. Yang XH, Richardson AL, Torres-Arzayus MI, Zhou P, Sharma C, Kazarov AR, Andzelm MM, Strominger JL, Brown M, Hemler ME. 2008. CD151 accelerates breast cancer by regulating alpha 6 integrin function, signaling, and molecular organization. Cancer Res. 68:3204-3213.
68. Evander M, Frazer IH, Payne E, Qi YM, Hengst K, McMillan NAJ. 1997. Identification of the a6 integrin as a candidate receptor for papillomaviruses. J. Virol. 71:2449-2456.
69. Spoden G, Freitag K, Husmann M, Boller K, Sapp M, Lambert C, Florin L. 2008. Clathrin-and caveolin-independent entry of human papillomavirus type 16-involvement of tetraspanin-enriched microdomains (TEMs). PLoS One 3:e3313. doi:10.1371/journal.pone.0003313.
70. Sarbassov DD, Ali SM, Sabatini DM. 2005. Growing roles for the mTOR pathway. Curr. Opin. Cell Biol. 17:596-603.
71. Wullschleger S, Loewith R, Hall MN. 2006. TOR signaling in growth and metabolism. Cell 124:471-484.
72. Joubert PE, Meiffren G, Gregoire IP, Pontini G, Richetta C, Flacher M, Azocar O, Vidalain PO, Vidal M, Lotteau V, Codogno P, Rabourdin-Combe C, Faure M. 2009. Autophagy induction by the pathogen receptor CD46. Cell Host. Microbe 6:354-366.
73. Pattingre S, Tassa A, Qu X, Garuti R, Liang XH, Mizushima N, Packer M, Schneider MD, Levine B. 2005. Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. Cell 122:927-939.
74. Shelly S, Lukinova N, Bambina S, Berman A, Cherry S. 2009. Autophagy is an essential component of Drosophila immunity against vesicular stomatitis virus. Immunity 30:588-598.
75. Aksamitiene E, Kiyatkin A, Kholodenko BN. 2012. Cross-talk between mitogenic Ras/MAPK and survival PI3K/Akt pathways: a fine balance. Biochem. Soc. Trans. 40:139-146.
76. Chaumorcel M, Lussignol M, Mouna L, Cavignac Y, Fahie K, Cotte-Laffitte J, Geballe A, Brune W, Beau I, Codogno P, Esclatine A. 2012. The human cytomegalovirus protein TRS1 inhibits autophagy via its interaction with Beclin 1. J. Virol. 86:2571-2584.
77. Orvedahl A, Alexander D, Tallóczy Z, Sun Q, Wei Y, Zhang W, Burns D, Leib DA, Levine B. 2007. HSV-1 ICP34.5 confers neurovirulence by targeting the Beclin 1 autophagy protein. Cell Host Microbe 1:23-35.
78. Shoji-Kawata S, Levine B. 2009. Autophagy, antiviral immunity, and viral countermeasures. Biochim. Biophys. Acta 1793:1478-1484.
79. Sinha S, Colbert CL, Becker N, Wei Y, Levine B. 2008. Molecular basis of the regulation of Beclin 1-dependent autophagy by the gammaherpesvirus 68 Bcl-2 homolog M11. Autophagy 4:989-997.
80. Tallóczy Z, Virgin HW, IV, Levine B. 2006. PKR-dependent autophagic degradation of herpes simplex virus type 1. Autophagy 2:24-29.
81. Griffin LM, Cicchini L, Pyeon D. Human papillomavirus infection is inhibited by host autophagy in primary human keratinocytes. Virology, in press.